title: Synchronous BRAF(V600E) and MEK inhibition leads to superior control of murine melanoma by limiting MEK inhibitor induced skin toxicity.
abstract: The BRAF inhibitor (BRAFi) treatment has led to impressive responses in BRAF(V600E) mutation-positive melanomas, but responses are not durable in many patients. As most of the BRAFi escape mechanisms involve ERK reactivation, combinations with MEK inhibitors (MEKi) are currently tested to improve BRAFi-mediated response durations. Additionally, such a combination is expected to reduce MEKi-induced skin toxicities, as these drugs are thought to have antagonistic effects on ERK activation in keratinocytes. However, preclinical in vivo data exploring the combination of BRAFi and MEKi to achieve improved tumor control in the absence of skin toxicities are limited. Using a murine Tyr::CreER(T2);Pten(LoxP/LoxP);Braf(CA/+) melanoma model, we have determined the effect of BRAFi and MEKi treatment and their combination on melanoma control and occurrence of adverse events. We found that the MEKi dosed beyond the maximum tolerable dose (MTD) led to stronger control of tumor growth than did the BRAFi, but mice had to be removed from treatment because of skin toxicity. The combination of BRAFi and MEKi reduced MEKi-associated skin toxicity. This allowed high and long-term dosing of the MEKi, resulting in long-term tumor control. In contrast to previous hypotheses, the addition of a BRAFi did not restore the MEKi-mediated downregulation of pERK1/2 in skin cells. Our data describe, for the first time, the alleviation of MEKi-mediated dose-limiting toxicity by addition of a BRAFi in a mouse melanoma model. Additional clinical Phase I studies should be implemented to explore MEKi dosing beyond the single drug MTD in combination with BRAFi.
authors.affiliation: Department of Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
authors.forename: Jules
authors.initials: J
authors.lastname: Gadiot
authors.affiliation: Department of Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
authors.forename: Anna I
authors.initials: AI
authors.lastname: Hooijkaas
authors.affiliation: Department of Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
authors.forename: Marcel A
authors.initials: MA
authors.lastname: Deken
authors.affiliation: Department of Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands ; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
authors.forename: Christian U
authors.initials: CU
authors.lastname: Blank
keywords: BRAF; MEK; melanoma; skin toxicity; trametinib; vemurafenib